Technical Analysis for APRE - Aprea Therapeutics, Inc.

Grade Last Price % Change Price Change
C 6.55 5.82% 0.36
APRE closed up 5.82 percent on Monday, March 18, 2024, on 70 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 5.82%
Wide Bands Range Expansion 5.82%
Gapped Up Strength 5.82%
Oversold Stochastic Weakness 5.82%
Calm After Storm Range Contraction 23.35%
Wide Bands Range Expansion 23.35%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 12 hours ago
Up 5% about 12 hours ago
Rose Above Previous Day's High about 14 hours ago
Rose Above 50 DMA about 14 hours ago
2x Volume Pace about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aprea Therapeutics, Inc. Description

Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor

Is APRE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.8465
52 Week Low 2.78
Average Volume 40,560
200-Day Moving Average 4.43
50-Day Moving Average 6.27
20-Day Moving Average 7.01
10-Day Moving Average 6.76
Average True Range 0.78
RSI (14) 49.49
ADX 29.74
+DI 22.36
-DI 25.47
Chandelier Exit (Long, 3 ATRs) 6.50
Chandelier Exit (Short, 3 ATRs) 7.39
Upper Bollinger Bands 8.83
Lower Bollinger Band 5.19
Percent B (%b) 0.37
BandWidth 51.88
MACD Line -0.02
MACD Signal Line 0.22
MACD Histogram -0.2371
Fundamentals Value
Market Cap 24.48 Million
Num Shares 3.74 Million
EPS 12.31
Price-to-Earnings (P/E) Ratio 0.53
Price-to-Sales 45.17
Price-to-Book 1.11
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.05
Resistance 3 (R3) 7.96 7.38 7.80
Resistance 2 (R2) 7.38 6.99 7.42 7.72
Resistance 1 (R1) 6.96 6.76 7.17 7.05 7.63
Pivot Point 6.38 6.38 6.48 6.42 6.38
Support 1 (S1) 5.96 5.99 6.17 6.05 5.47
Support 2 (S2) 5.38 5.76 5.42 5.38
Support 3 (S3) 4.96 5.38 5.30
Support 4 (S4) 5.05